UBS cuts estimates on Alexion Pharmaceuticals (ALXN +3.1%), and lowers its price target to $53...

|About: Alexion Pharmaceuticals, ... (ALXN)|By:, SA News Editor

UBS cuts estimates on Alexion Pharmaceuticals (ALXN +3.1%), and lowers its price target to $53 from $55, keeping a Neutral rating on the firm. Shares are outgaining all issues listed on the NASDAQ-100.